MedPath

ERAS in Colorectal Surgery Diminishes the Negative Impact of Sarcopenia on Short Term Outcomes

Completed
Conditions
Sarcopenia
Colonic Neoplasms
Registration Number
NCT02618811
Lead Sponsor
Jagiellonian University
Brief Summary

So far, the impact of sarcopenia has been analysed only in patients undergoing traditional surgical procedures (laparotomy) or those with metastatic spread. As the ERAS protocol combined with minimally invasive access decreases postoperative metabolic disorders, it seems possible that it can limit the deleterious impact of sarcopenia as well. The aim of this study was to investigate whether the use of ERAS protocol in colorectal cancer patients influences the postoperative risk due to sarcopenia.

Detailed Description

The prospective observation with post-hoc analysis of 171 consecutive colorectal cancer patients was performed. In all patients 16-item ERAS protocol was applied.

Contrast-enhanced CT scan was performed preoperatively. From each scan one CT image at the level of L3 vertebra was transferred in Digital Imaging and Communications in Medicine format (DICOM) and anonymised. Firstly, the threshold range between -29 and +150 Hounsfield units was set to semi-automatically outline muscle areas, - 150 to - 50 was used for visceral adipose tissue areas, and -190 to -30 was used for subcutaneous and intermuscular adipose tissue areas. Secondly, the software calculated the surface area (cm2) of each tissue. The L3 skeletal muscle area (rectus abdominis, external and internal obliques, transversus abdominis, quadratus lumborum, psoas, erector spinae) normalized for patient height was used to calculate skeletal muscle index (SMI) (cm2/m2).

According to Martin et al. sarcopenia was defined as a SMI \<41 cm2/m2 in women, \<43 cm2/m2 in men with a BMI \<25 kg/m2, and \<53 cm2/m2 in men with a BMI \>25 kg/m2 (10). To assess for myosteatosis the mean radiodensity of a L3 psoas muscle was measured. The cut-off for patients with BMI \<25 kg/m2 was \<41 Hounsfield units and \<33 Hounsfield units for patients with BMI ≥25 kg/m2.

For the purposes of further analysis the entire group of patients was divided into subgroups depending on the presence of sarcopenia or myosteatosis.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
171
Inclusion Criteria
  • confirmed adenocarcinoma of colon or rectum
  • complete preoperative radiology assessment with abdominal CT scan
  • laparoscopic resection
  • perioperative care according to ERAS principles
Exclusion Criteria
  • unavailability of a preoperative abdominal CT scan (within 30 days prior surgery)
  • emergency or initially open surgery
  • patients treated with endoscopic techniques: transanal endoscopic microsurgery (TEM), transanal total mesorectal excision (TaTME)
  • concomitant inflammatory bowel diseases.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Complicationsup to 30 days post surgery
Secondary Outcome Measures
NameTimeMethod
Mobilization on the 1st postoperative dayup to discharge from hospital, an average 6 days

walking at least 100 m without assistance, at least 6h out of bed (sitting, walking)

Need for opioid analgesia postoperativelyup to discharge from hospital, an average 6 days

no need for opioid drug administration (any kind, dosage or administration route)

Hospital length of stay (days)up to discharge from hospital, an average 6 days
Compliance with ERAS protocol (%)up to discharge from hospital, an average 6 days
Tolerance of oral diet on the 1st postoperative dayup to discharge from hospital, an average 6 days

tolerating at least 800 ml of clear water/fluids and 1 oral nutritional supplement within the first 24h postoperative hours

Time to first flatusup to discharge from hospital, an average 6 days
Readmission rateup to 30 days post surgery

Trial Locations

Locations (1)

2nd Department of General Surgery, Jagiellonian University

🇵🇱

Kraków, Poland

© Copyright 2025. All Rights Reserved by MedPath